Phaseline

Companies › Sequence LifeScience

Sequence LifeScience: clinical trials, targets and expected readouts

6 active drug programs in 10 registered trials: 10 Phase 4; Metabolic and endocrine, Immunology; next expected readout Jul 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Activate™ Matrix
Acellular matrix product for wound healing
–Phase 4Diabetic Foot Ulcer; Skin UlcerJul 2027
AmnioDefend™ FT Matrix
Acellular matrix product for wound healing
–Phase 4Diabetic Foot Ulcer; Skin UlcerJul 2027
Enclose™ TL Matrix
Acellular tissue-derived matrix scaffold
–Phase 4Diabetic Foot UlcerJul 2027
Palisade™ DM Matrix
Acellular matrix product for wound healing
–Phase 4Diabetic Foot Ulcer; Skin UlcerJul 2027
Sentry™ SL Matrix
Acellular matrix product for wound healing
–Phase 4Diabetic Foot Ulcer; Skin UlcerJul 2027
Shelter™ DM Matrix
Acellular dermal matrix for diabetic foot ulcer wound healing
–Phase 4Diabetic Foot UlcerJul 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07086443Activate™ MatrixPhase 4Diabetic Foot UlcerMetabolic and endocrineJul 2027
NCT07086443AmnioDefend™ FT MatrixPhase 4Diabetic Foot UlcerMetabolic and endocrineJul 2027
NCT07086443Palisade™ DM MatrixPhase 4Diabetic Foot UlcerMetabolic and endocrineJul 2027
NCT07086443Enclose™ TL MatrixPhase 4Diabetic Foot UlcerMetabolic and endocrineJul 2027
NCT07086443Sentry™ SL MatrixPhase 4Diabetic Foot UlcerMetabolic and endocrineJul 2027
NCT07086443Shelter™ DM MatrixPhase 4Diabetic Foot UlcerMetabolic and endocrineJul 2027
NCT07665268Activate™ MatrixPhase 4Skin UlcerImmunologyJan 2028
NCT07665268AmnioDefend™ FT MatrixPhase 4Skin UlcerImmunologyJan 2028
NCT07665268Palisade™ DM MatrixPhase 4Skin UlcerImmunologyJan 2028
NCT07665268Sentry™ SL MatrixPhase 4Skin UlcerImmunologyJan 2028

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Applied Biologics Tiger Biosciences BioLab Holdings Yong Zhao, MD, PhD Biocomposites

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.